ARTICLE | Company News
Aciex Therapeutics, Portola deal
March 4, 2013 8:00 AM UTC
Portola granted Aciex exclusive rights to co-develop Portola's portfolio of small molecule dual spleen tyrosine kinase (SYK) and Janus kinase (JAK) inhibitors for ophthalmic indications. The portfoli...